The stock of Moderna Inc (NASDAQ:MRNA) registered an increase of 22.39% in short interest. MRNA’s total short interest was 11.44M shares in March as published by FINRA. Its up 22.39% from 9.35 million shares, reported previously. With 878,100 shares average volume, it will take short sellers 13 days to cover their MRNA’s short positions. The short interest to Moderna Inc’s float is 33.3%.
The stock increased 4.80% or $1 during the last trading session, reaching $21.82. About 1.16 million shares traded or 4.58% up from the average. Moderna, Inc. (NASDAQ:MRNA) has 0.00% since March 17, 2018 and is . It has underperformed by 4.37% the S&P500.
Marina Biotech, Inc., a biopharmaceutical company, engages in the discovery, acquisition, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. The company has market cap of $7.18 billion. The firm has three clinical development programs, such as IT-102 and IT-103, a celecoxib program drug candidates for the treatment of combined arthritis pain/hypertension and the treatment of pain requiring a high dose of celecoxib; CEQ508, an oral delivery of small interfering RNA against beta-catenin, combined with IT-102 to suppress polyps in the precancerous syndrome and orphan indication of familial adenomatous polyposis; and CEQ508 combined with IT-103 to treat colorectal cancer. It currently has negative earnings. The Company’s preclinical pipeline includes oligotherapeutics for the treatment of bladder cancer, inflammatory bowel, and duchenne muscular dystrophy diseases.
More notable recent Moderna, Inc. (NASDAQ:MRNA) news were published by: Gurufocus.com which released: “Mar 13, 2019 – Moderna Inc (MRNA) Files 10-K for the Fiscal Year Ended on December 31, 2018 – GuruFocus.com” on March 13, 2019, also Fiercebiotech.com with their article: “BioNTech lines up $800M Nasdaq IPO to fuel mRNA R&D: Reuters – FierceBiotech” published on March 13, 2019, Seekingalpha.com published: “Moderna up 4% premarket on positive early-stage data supporting potential of mRNA encoding as regenerative therapeutic – Seeking Alpha” on February 20, 2019. More interesting news about Moderna, Inc. (NASDAQ:MRNA) were released by: Nasdaq.com and their article: “Translate Bio to Present at the 39th Annual Cowen and Company Healthcare Conference – Nasdaq” published on March 04, 2019 as well as Businesswire.com‘s news article titled: “Moderna Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights Recent Pipeline Progress – Business Wire” with publication date: March 06, 2019.